Ivana Ivanišević Zlački
banner
ivanaiz.bsky.social
Ivana Ivanišević Zlački
@ivanaiz.bsky.social
🌼 Mother of a beautiful daughter💊 MPharm, Passionate about healthcare and making an impact in oncology care 🎨 Fashion, Art, Music and Dance lover🔬 Curious about science and innovation 🌍 Advocate for "live and let live" philosophy🙋‍♀️Working in pharma
Reposted by Ivana Ivanišević Zlački
Doing, and being impactful while you’re doing it .. that’s the biggest observation I have when I see people that are growing versus people who are misstepping or failing at their quests. Too many think they’re doing when they’re actually posturing or wasting time on things that don’t matter ..
November 27, 2024 at 3:26 PM
Reposted by Ivana Ivanišević Zlački
in NIAGARA Adding perioperative durvalumab (DURVA) to neoadjuvant gemcitabine and cisplatin (GC) significantly improves event-free survival (EFS) and overall survival (OS) in patients, without causing delays in radical cystectomy (RC).
#BLADDR24
Day One of #BLADDR24
Dr Maria De Santis
MIBC ESMO congress highlights #BladderCancer

Perioperative durvalumab to neoadj gemcitabine & cisplatin improves EFS & OS, w/o delays in radical cystectomy

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
November 27, 2024 at 12:03 PM
Reposted by Ivana Ivanišević Zlački
Day One of #BLADDR24
Dr Gunhild von Amsberg

Presentation on first-line treatment for advanced urothelial carcinoma highlights the need to balance efficacy, safety, patient characteristics,& QoL.

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
November 27, 2024 at 2:47 PM
Reposted by Ivana Ivanišević Zlački
Day 1 of #BLADDR24
Dr. Petros Grivas

The concept of withholding radical treatment, such as radical cystectomy (RC) or radiotherapy, for patients with a clinical complete response (cCR) after neoadjuvant or induction systemic therapy is emerging as a potential future approach in #BladderCancer MGt
November 27, 2024 at 4:31 PM
November 26, 2024 at 9:18 PM
Reposted by Ivana Ivanišević Zlački
Remember new users are coming on daily, unsure of engagement. The more posts you like and reply to, the strong the platform becomes !
November 25, 2024 at 7:05 PM
Reposted by Ivana Ivanišević Zlački
Since #oncsky is forming here just wanted to post about the origins of the healthcare hashtags, all of which used "sm" to anchor = social media
jamanetwork.com/journals/jam... 1/3
Disease-Specific Hashtags for Online Communication About Cancer Care
This study highlights the usefulness of agreement on disease-specific hashtags for effective online communication about cancer care.
jamanetwork.com
November 22, 2024 at 10:52 AM
Reposted by Ivana Ivanišević Zlački
Once you believe this, once you live this …. EVERYTHING CHANGES.. I know everyone has 3 people in their lives that could use this, I’m excited about this clip, I know it’s gonna wake someone up today 🔑🔑☀️🔑☀️🔑☀️☀️☀️

PS: text me for any follow up questions at 📲: 1-212-931-5731
November 22, 2024 at 1:39 PM
Reposted by Ivana Ivanišević Zlački
Literally..
November 22, 2024 at 1:57 PM
Reposted by Ivana Ivanišević Zlački
OncoAlert🚨 RoundUp September Nov 14-21
REGISTER: www.OncoAlert360.com OR buff.ly/48Xpgz0
November 22, 2024 at 1:58 PM
Reposted by Ivana Ivanišević Zlački
"The social network that was once so key to cancer patient advocacy has become far less useful for me," writes @jfreemandaily.bsky.social www.statnews.com/2024/11/22/t... #OncSky #ptadvocacy
Why cancer advocates like me are leaving X
“It’s sad to see the era of Twitter cancer communities end,” writes cancer advocate Janet Freeman-Daily.
www.statnews.com
November 22, 2024 at 1:59 PM
Reposted by Ivana Ivanišević Zlački
What are the implications for health care of our increasingly fragmented news sources, I wonder. @columjournreview.bsky.social www.cjr.org/the_media_to...? #HealthJournalism
Our Fragmented Media Age, and What Might Come Next
Some potential new models for journalism might in fact be old ones.
www.cjr.org
November 22, 2024 at 2:05 PM
Reposted by Ivana Ivanišević Zlački
Study assessed #LungCancer screening (LCS) using low-dose computed tomography (LDCT) in high tuberculosis-burden countries
The SPR was higher with NLST criteria compared to Lung-RADS, although LCDR was similar across both criteria. Lung-RADS was found to be preferable
https://buff.ly/4fEtTAq
November 22, 2024 at 2:13 PM